CliffBio
small molecule

BRIVIACT

BRIVARACETAM

Loss of exclusivityApril 2030latest FDA-listed patent expiry
CompanyUCB →See this company's full patent-cliff portfolio

Drug detail

Brand nameBRIVIACT
Active ingredientBRIVARACETAM
Strength25MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2016
Marketing statusRX

Listed patents

PatentExpiresType
10729653April 2030product
6911461February 2026substance, product

More from UCB

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

BRIVIACT patent cliff — loss of exclusivity April 2030 | CliffBio